Los Angeles Capital Management LLC Sells 26,191 Shares of Harrow, Inc. (NASDAQ:HROW)

Los Angeles Capital Management LLC trimmed its holdings in Harrow, Inc. (NASDAQ:HROW) by 60.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,918 shares of the company’s stock after selling 26,191 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Harrow were worth $568,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after acquiring an additional 227 shares in the last quarter. Quest Partners LLC bought a new position in shares of Harrow during the 3rd quarter worth about $29,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Harrow by 10.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock worth $253,000 after purchasing an additional 727 shares in the last quarter. Calamos Advisors LLC grew its stake in shares of Harrow by 35.2% in the 4th quarter. Calamos Advisors LLC now owns 11,913 shares of the company’s stock valued at $400,000 after buying an additional 3,103 shares during the period. Finally, Bleakley Financial Group LLC increased its position in Harrow by 63.1% in the 4th quarter. Bleakley Financial Group LLC now owns 8,770 shares of the company’s stock valued at $294,000 after buying an additional 3,394 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Price Performance

Shares of NASDAQ HROW opened at $25.63 on Tuesday. The stock has a market cap of $912.81 million, a price-to-earnings ratio of -27.27 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. Harrow, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $59.23. The firm’s 50-day simple moving average is $32.35 and its 200 day simple moving average is $39.93.

Wall Street Analysts Forecast Growth

HROW has been the topic of several recent research reports. HC Wainwright started coverage on Harrow in a report on Thursday, February 6th. They issued a “buy” rating and a $57.00 price target on the stock. B. Riley cut their target price on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.